Parkinsonism—Drug Treatment: Part I

Berg, Mary; Ebert, Barbara E.; Willis, Debra K.; Host, Toni; Fincham, Richard W.; Schottelius, Dorothy D.

doi:10.1177/10600280870211p101

Cited by 11 publications

(4 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some of the symptoms of this disease can also be alleviated by inhibiting ACh activities (Berg et al 1987). These findings also suggest that ACh-DA interactions in the striatum are important in regulating motor function.…”

Section: Functional Interactions Between Dopaminergic and Cholinergicmentioning

confidence: 95%

Aging of the striatum: mechanisms and interventions

Umegaki

Roth

Ingram

2008

AGE

View full text Add to dashboard Cite

Motor function declines with increasing adult age. Proper regulation of the balance between dopamine (DA) and acetylcholine (ACh) in the striatum has been shown to be fundamentally important for motor control. Although other factors can also contribute to this age-associated decline, a decrease in the concentration and binding potential of the DA D(2) receptor subtype in the striatum, especially in the cholinergic interneurons, are involved in the mechanism. Our studies have shown that gene transfer of the DA D(2) receptor subtype with adenoviral vectors is effective in ameliorating age-associated functional decline of the striatal cholinergic interneurons. These achievements confirm that an age-associated decrease of D(2)R contributes functional alteration of the interaction of DA and ACh in the striatum and demonstrate that these age-associated changes indeed are modifiable.

show abstract

Section: Functional Interactions Between Dopaminergic and Cholinergicmentioning

confidence: 95%

Aging of the striatum: mechanisms and interventions

Umegaki

Roth

Ingram

2008

AGE

View full text Add to dashboard Cite

show abstract

“…At low doses, bromocriptine acts as a pre-synaptic D2 agonist, and thereby reduces dopaminergic release and function in dopaminergically mediated systems. Its net effect at mid-range doses appears to augment the function of cerebral dopaminergic systems [13]. Passler et al (2001) [122] observed bromocriptine treatmentrelated improvements in arousal (i.e.…”

Section: Bromocriptinementioning

confidence: 99%

Pharmacotherapy of Posttraumatic Cognitive Impairments

Arciniegas

Silver

2006

Behavioural Neurology

View full text Add to dashboard Cite

Pharmacotherapy may contribute to the rehabilitation of persons with posttraumatic cognitive impairments. This article reviews first the neurobiological consequences of traumatic brain injury with a particular emphasis on acute and long-term posttraumatic neurochemical disturbances. Studies of pharmacotherapies for posttraumatic cognitive impairments are reviewed next, and are organized according to medication class and the neurotransmitter system they affect most. Based on the evidence provided by that review, augmentation of posttraumatic cerebral catecholaminergic and cholinergic function are suggested as potentially useful neurochemical targets for pharmacologic intervention in this population. More specifically, it is suggested that persons with posttraumatic impairments in arousal, speed of processing, and possibly attention may benefit most from treatment with an agent that augments cerebral catecholaminergic function, and that persons whose predominant posttraumatic impairment is in the domain of memory may benefit most from treatment with cholinesterase inhibitors. Practical considerations regarding the use of pharmacotherapies for posttraumatic cognitive impairments are offered, and the need for additional research in this area is highlighted.

show abstract

“…Extensive use in adults appears not to be associated with significant risks. Nausea and vomiting, orthostatic hypertension, nasal congestion, and transient hepatic enzyme elevations are the most common adverse events (29). The hallucinosis and psychotic symptoms seen when DA agonists and L-dopa are administered to patients with (usually) advanced Parkinson's disease were not seen in this pilot.…”

Section: This Pilot Of the D A Agonist Pergolide In Gts Ismentioning

confidence: 83%

Dopamine agonist treatment of tourette disorder in children: Results of an open‐label trial of pergolide

et al. 1997

View full text Add to dashboard Cite

This exploratory study was meant to determine the effect of the dopamine (DA) agonist pergolide on Gilles de la Tourette syndrome (GTS) in children and adolescents and to ascertain correlates of pergolide response. Thirty-two outpatients, aged 7-19 years, were systemically assessed in a neuropsychiatric clinic for the presence of GTS and comorbid disorders. After a 6-week open-label, fixed-flexible dosing schedule, response to pergolide on standard GTS severity outcome measures was assessed. Overall, 75% of patients (24/32) had a > 50% drop in their tic severity rating from baseline with a mean treatment dosage of 177 +/- 61 micrograms/day. Highly significant (p = 0.0001) baseline to week 6 differences were demonstrated in all tic symptom measures. The presence of restless legs syndrome (RLS) comorbidity (59%) was highly associated with a positive response. These results suggest DA agonism as a strategy, and pergolide in particular, may be a practical form of therapy for GTS. Response predictors of patient comorbid RLS argue for its further study with regard to GTS.

show abstract

Parkinsonism—Drug Treatment: Part I

Cited by 11 publications

References 92 publications

Aging of the striatum: mechanisms and interventions

Aging of the striatum: mechanisms and interventions

Pharmacotherapy of Posttraumatic Cognitive Impairments

Dopamine agonist treatment of tourette disorder in children: Results of an open‐label trial of pergolide

Contact Info

Product

Resources

About